Health
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
RAHWAY, N.J., February 12, 2026--Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/001343a91178d8a945dfe06d655fd96d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Nz1v_cdS3UVAA0nF_s8syw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/001343a91178d8a945dfe06d655fd96d","width":480,"height":217}},"lazy":false},{"type":"text","content":"Late-breaking KEYNOTE-B15 data show KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response rates for patients with certain types of bladder cancer","length":250,"tagName":"p","attribs":{}},{"type":"text","content":"New LITESPARK-022 and LITESPARK-011 data highlight the disease-free survival benefit of WELIREG® (belzutifan) plus KEYTRUDA and progression-free survival benefit of WELIREG in combination with LENVIMA® (lenvatinib), respectively","length":228,"tagName":"p","attribs":{}},{"type":"text","content":"All three studies will be featured in the official ASCO GU Press Program","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J., February 12, 2026--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that data across multiple genitourinary cancers from several approved and investigational medicines will be presented at the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium from Feb. 26-28. These data, including three studies that will be featured in the symposium’s press program, underscore Merck’s commitment to advancing research across its broad portfolio to improve patient outcomes.","length":565,"tagName":"p"},{"type":"text","content":""We’re excited to share new results from our portfolio and pipeline for more patients with certain types of bladder and kidney cancers, with new data in muscle invasive bladder cancer and earlier stages of renal cell carcinoma," said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. "The results we’re presenting at ASCO GU underscore our leadership across the genitourinary cancer landscape and our...